Samira Chamyani - Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, ۴۵۱۳۷-۶۶۷۳۱, Iran
Hamid R. Shahsavari - Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, ۴۵۱۳۷-۶۶۷۳۱, Iran
Mehri Khatami - Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, ۴۵۱۳۷-۶۶۷۳۱, Iran

Platinum complexes are well-established drugs in modern anticancer chemotherapy.However, their effectiveness is still hindered by clinical problems, including acquiredor intrinsic resistance, a limited spectrum of activity, and high toxicity leading to side effects [1]. A recent strategy in the field of metal based anticancer drugs consists in the design of bimetallic or even multimetallic agents bearing diverse metal centers with distinct biological and pharmacological features. This strategy is aimed at exploiting the possible synergism existing among the individual metal centers, which may contribute to overcome resistance [2]. We report here on the preparation, characterization and stability of some bimetallic Pt(II)–Au(I) complexes. The new compounds are depicted in Fig 1. They contain a cycloplatinated(II) moiety and a gold(I) chloride fragment linked through a bifunctional diphosphane ligand 1,1-bis(diphenylphosphino)methane (dppm).